USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
APELIOTUS TECHNOLOGIES, INC.
Address:
1456 N MORNINGSIDE DR NE
ATLANTA, GA 30306 3240
Phone:
N/A
URL:
N/A
EIN:
200730798
DUNS:
143313430
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $431,704.00 3
SBIR Phase II $1,118,985.00 1
STTR Phase I $139,832.00 1

Award List:

Diagnostic for Age-Related Macular Degeneration

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Apeliotus Technologies proposes to develop a commercial diagnostic for the early detection of age-related macular degeneration (ARMD). It relies on a functional test of dark adaptation kinetics (the transition from being light-adapted to being dark-adapted) that… More

Polymer Stentgraft for Treatment of Cerebral Aneurysms

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$189,146.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Apeliotus Technologies proposes to develop a polymer stentgraft for the treatment of cerebral aneurysms. The stentgraft is formed from coaxial inner and outer tubes of elastomeric polymer, with the gap between the tubes filled by an uncured liquid adhesive. The… More

Diagnostic for Age-Related Macular Degeneration

Award Year / Program / Phase:
2007 / SBIR / Phase II
Award Amount:
$1,118,985.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This is an SBIR Phase II proposal directed at the continued development of a diagnostic for the early detection of age-related macular degeneration (AMD). It relies on a functional test of dark adaptation kinetics (the transition from being light-adapted to… More

Topical Treatment for Mild Psoriasis

Award Year / Program / Phase:
2007 / STTR / Phase I
Award Amount:
$139,832.00
Agency:
HHS
Principal Investigator:
Research Institution:
MEDICAL COLLEGE OF GEORGIA
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): This STTR Phase I proposal is directed at the development of a topical treatment for mild psoriasis. It is based on the recent discovery of a cell signaling module important for the regulation of keratinocyte proliferat ion and differentiation. This signaling… More

AdaptRx: Surrogate Marker for Vision Loss in AMD

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$142,558.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Apeliotus Technologies proposes to develop a new clinical trial endpoint for age-related macular degeneration (AMD) based on dark adaptation. A major challenge in attacking AMD is the lack of adequate clinical trial end points. Visual acuity is currently the only… More